Foff Erin Pennock 4
4 · MapLight Therapeutics, Inc. · Filed May 6, 2026
Research Summary
AI-generated summary of this filing
MapLight (MPLT) CMO Erin Pennock Foff Sells Shares
What Happened
- Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics (MPLT), sold a total of 50,280 shares in multiple open‑market transactions executed May 4–6, 2026. The combined proceeds reported were $1,427,594.
- Individual reported lots: 9,180 @ $27.50 ($252,450); 5,460 @ $28.37 ($154,900); 312 @ $29.56 ($9,223); 700 @ $30.08 ($21,056); 9,645 @ $28.12 ($271,217); 931 @ $29.00 ($26,999); 8,152 @ $28.04 ($228,582); and 15,900 @ $29.13 ($463,167). These are sales (routine disposition of shares), not purchases.
Key Details
- Transaction dates: May 4–6, 2026. Form filed on May 6, 2026 reporting the period May 4, 2026.
- Total shares sold: 50,280. Total proceeds: $1,427,594.
- 10b5‑1 plan: The filing notes at least one transaction was made pursuant to a Rule 10b5‑1 trading plan adopted by the reporting person on December 29, 2025 (see footnote F1).
- Price reporting: Many line items use weighted average prices; the filing includes footnotes showing the ranges of individual trade prices (see F2–F9 for ranges roughly spanning ~$26.84 to ~$30.55).
- Shares owned after the transactions: Not specified in the excerpt provided — check the full Form 4 for post‑trade holdings.
- Timeliness: Filing date is May 6, 2026; no late‑filing flag was provided in the data you supplied.
Context
- Sales by executives are often routine (e.g., part of pre‑arranged plans or diversification) and do not, by themselves, indicate a change in company outlook. The presence of a Rule 10b5‑1 plan means at least some trades were pre‑scheduled.
- For full details (exact per‑trade timestamps, exact per‑trade prices within the reported weighted averages, and current holdings), consult the official Form 4 (Accession No. 0002021233-26-000008) on the SEC EDGAR site.
Insider Transaction Report
Form 4
Foff Erin Pennock
Chief Medical Officer
Transactions
- Sale
Voting Common Stock
[F1][F2]2026-05-04$27.50/sh−9,180$252,450→ 391,597 total - Sale
Voting Common Stock
[F1][F3]2026-05-04$28.37/sh−5,460$154,900→ 386,137 total - Sale
Voting Common Stock
[F1][F4]2026-05-04$29.56/sh−312$9,223→ 385,825 total - Sale
Voting Common Stock
[F1][F5]2026-05-04$30.08/sh−700$21,056→ 385,125 total - Sale
Voting Common Stock
[F1][F6]2026-05-05$28.12/sh−9,645$271,217→ 375,480 total - Sale
Voting Common Stock
[F1][F7]2026-05-05$29.00/sh−931$26,999→ 374,549 total - Sale
Voting Common Stock
[F1][F8]2026-05-06$28.04/sh−8,152$228,582→ 366,397 total - Sale
Voting Common Stock
[F1][F9]2026-05-06$29.13/sh−15,900$463,167→ 350,497 total
Footnotes (9)
- [F1]This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 29, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.84 to $27.835 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.845 to $28.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.9669 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $28.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.80 to $29.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.675 to $28.6587 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.71 to $29.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Signature
/s/ Kristopher L. Hanson, Attorney-in-Fact|2026-05-06